Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Transthyretin cardiac amyloidosis (ATTR‐CA) demonstrates progressive, potentially fatal,
and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin‐derived …

Aims We aimed to assess carpal tunnel syndrome (CTS) prevalence in transthyretin (TTR)‐
related and light‐chain amyloidosis (AL), comparing it to the general population, adjusted for …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Objectives Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy
(ATTR-CM), this study aimed to determine whether there is a differential effect between …

Aim Systematic evidence on the prevalence and clinical outcome of transthyretin
amyloidosis (ATTR) is missing. We explored:(i) the prevalence of cardiac amyloidosis in …

Introduction ATTRv amyloidosis is worldwide spread with endemic foci in Portugal and
Sweden, Japan, Brazil, Maiorca, and Cyprus. A national Registry was developed to …

Background: The p. Val142Ile variant, predominantly found among people of African
descent, is the most common cause of variant transthyretin amyloidosis and carriers …

Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy characterized by extracellular
deposition of mis-folded proteins called amyloid. Cardiac complications of CA are several …

Background: Over the past decade, three new drugs have been approved for the treatment
of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to …